Cargando…

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()

Prostate cancer is a leading cause of cancer death in men in developed countries. Once the tumor has achieved a castration-refractory metastatic stage, treatment options are limited with the average survival of patients ranging from two to three years only. Recently, new drugs for treatment of castr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heidegger, Isabel, Massoner, Petra, Eder, Iris E., Pircher, Andreas, Pichler, Renate, Aigner, Friedrich, Bektic, Jasmin, Horninger, Wolfgang, Klocker, Helmut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pergamon 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834152/ https://www.ncbi.nlm.nih.gov/pubmed/23792785 http://dx.doi.org/10.1016/j.jsbmb.2013.06.002

Ejemplares similares

High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
por: Heidegger, Isabel, et al.
Publicado: (2015)

Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program
por: Heidegger, Isabel, et al.
Publicado: (2015)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

Acceptance of female urologists among patients with suspected prostate disease
por: Steinkohl, Fabian, et al.
Publicado: (2021)

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature
por: Pircher, Andreas, et al.
Publicado: (2019)

Antidiabetic drugs influence molecular mechanisms in prostate cancer
por: Pircher, Andreas, et al.
Publicado: (2018)

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
por: Ladurner, Michael, et al.
Publicado: (2021)

Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo
por: Ofer, Philipp, et al.
Publicado: (2015)

ASCO 2018: highlights of urothelial cancer and prostate cancer
por: Pichler, Renate, et al.
Publicado: (2018)

Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis
por: Heidegger, Isabel, et al.
Publicado: (2014)

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
por: Oberaigner, Willi, et al.
Publicado: (2011)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
por: Kafka, Mona, et al.
Publicado: (2020)

Cholesterol pathway the Achilles heel in prostate cancer metastasis
por: Heidegger, Isabel, et al.
Publicado: (2018)

Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
por: Junker, Daniel, et al.
Publicado: (2013)

Adenomatoid tumor of the testis mimicking malignant testicular cancer on multiparametric ultrasound
por: Pichler, Renate, et al.
Publicado: (2018)

Potentials and Limitations of Real-Time Elastography for Prostate Cancer Detection: A Whole-Mount Step Section Analysis
por: Junker, Daniel, et al.
Publicado: (2012)

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response
por: Kafka, Mona, et al.
Publicado: (2022)

The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
por: Maffey-Steffan, Johanna, et al.
Publicado: (2019)

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)

Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy
por: Heidegger, Isabel, et al.
Publicado: (2019)

Enhanced Inhibition of Prostate Tumor Growth by Dual Targeting the Androgen Receptor and the Regulatory Subunit Type Iα of Protein Kinase A in Vivo
por: Eder, Iris E., et al.
Publicado: (2013)

Long term disease free survival with multimodal therapy in small cell bladder cancer
por: Heidegger, Isabel, et al.
Publicado: (2016)

Organ-Sparing Surgery in Testicular Tumor: Is This the Right Approach for Lesions ≤ 20 mm?
por: Staudacher, Nina, et al.
Publicado: (2020)

Mitochondrial Haplogroups and Control Region Polymorphisms Are Not Associated with Prostate Cancer in Middle European Caucasians
por: Mueller, Edith E., et al.
Publicado: (2009)

The Use of Dietary Supplements to Alleviate Androgen Deprivation Therapy Side Effects during Prostate Cancer Treatment
por: Dueregger, Andrea, et al.
Publicado: (2014)

Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality
por: Pircher, Andreas, et al.
Publicado: (2017)

Gender-related Outcome in Bladder Cancer Patients undergoing Radical Cystectomy
por: Pichler, Renate, et al.
Publicado: (2017)

Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study
por: Pichler, Renate, et al.
Publicado: (2017)

The Impact of Cand1 in Prostate Cancer
por: Eigentler, Andrea, et al.
Publicado: (2020)

Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer
por: Massoner, P, et al.
Publicado: (2010)

Ultrasound of the prostate
por: Mitterberger, Michael, et al.
Publicado: (2010)

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer
por: Schaefer, G, et al.
Publicado: (2013)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells
por: Puhr, Martin, et al.
Publicado: (2014)

High IDO‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
por: Seeber, Andreas, et al.
Publicado: (2018)

Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model
por: Mühlberger, Nikolai, et al.
Publicado: (2017)

Do we need repeated CT imaging in uncomplicated blunt renal injuries? Experiences of a high-volume urological trauma centre
por: Lindner, Andrea Katharina, et al.
Publicado: (2022)

PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy
por: Pichler, Renate, et al.
Publicado: (2017)

The transcription factor CUX1 negatively regulates invasion in castrate resistant prostate cancer
por: Dorris, Emma R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fac43gv1954hksp64625ma4m3l